
    
      The study was prematurely terminated based on the results of an interim analysis where BAF312
      did not demonstrate superior efficacy over placebo and a dose-response relationship was not
      observed. There were no safety concerns. Approximately 56 participants were planned to be
      randomized. A total of 17 participants were enrolled and randomized by the time the study was
      terminated.
    
  